Roberto Petrioli1, Edoardo Francini2, Anna Ida Fiaschi3, Letizia Laera4, Salvatora Tindara Miano4, Giovanni De Rubertis5, Giandomenico Roviello4. 1. Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy r.petrioli@ao-siena.toscana.it. 2. Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, Italy. 3. Pharmacology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. 4. Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. 5. Urology Unit, Department of Genitourinary Diseases, University of Siena, Siena, Italy.
Abstract
AIM: The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily. RESULTS: Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients. CONCLUSION: Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC. Copyright
AIM: The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily. RESULTS: Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients. CONCLUSION: Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC. Copyright
Authors: Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889